1. Closing the Gaps in Care of Dyslipidemia: Revolutionizing Management with Digital Health and Innovative Care Models.
- Author
-
Apple SJ, Clark R, Daich J, Gonzalez ML, Ostfeld RJ, Toth PP, Bittner V, Martin SS, Rana JS, Nasir K, Shapiro MD, Virani SS, and Slipczuk L
- Abstract
Although great progress has been made in the diagnostic and treatment options for dyslipidemias, unawareness, underdiagnosis and undertreatment of these disorders remain a significant global health concern. Growth in digital applications and newer models of care provide novel tools to improve the management of chronic conditions such as dyslipidemia. In this review, we discuss the evolving landscape of lipid management in the 21st century, current treatment gaps and possible solutions through digital health and new models of care. Our discussion begins with the history and development of value-based care and the national establishment of quality metrics for various chronic conditions. These concepts on the level of healthcare policy not only inform reimbursements but also define the standard of care. Next, we consider the advances in atherosclerotic cardiovascular disease risk score calculators as well as evolving imaging modalities. The impact and growth of digital health, ranging from telehealth visits to online platforms and mobile applications, will also be explored. We then evaluate the ways in which machine learning and artificial intelligence-driven algorithms are being utilized to address gaps in lipid management. From an organizational perspective, we trace the redesign of medical practices to incorporate a multidisciplinary team model of care, recognizing that atherosclerotic cardiovascular disease risk is multifaceted and requires a comprehensive approach. Finally, we anticipate the future of dyslipidemia management, assessing the many ways in which atherosclerotic cardiovascular disease burden can be reduced on a population-wide scale., Competing Interests: Robert Ostfeld receives research grants from the Purjes and Greenbaum Foundations; and scientific advisory board member, Mesuron Inc., with stock options. Vera Bittner served on the Steering Committee for the Odyssey Outcomes Trial (Sanofi and Regeneron), served as National Coordinator for the CLEAR Outcomes Trial (Esperion), the STRENGTH Trial (Astra Zeneca), and the DalGene Trial (DalCor); she is Site PI for ORION (Novartis) and EVOLVE-MI (Amgen), and is co-investigator on an industry/academic collaboration between Amgen and the UAB School of Public Health (PIs: Muntner and Colantonio). All monies for these activities go to the institution. VB serves on a DSMB for Verve Therapeutics and serves as Senior Guest Editor for Circulation and receives personal honoraria for these activities. Seth Martin reports funding from the American Heart Association (20SFRN35380046, 20SFRN35490003, COVID19-811000, #878924, #882415, and #946222), the Patient-Centered Outcomes Research Institute (ME-2019C1-15 328, IHS-2021C3-24147), the National Institutes of Health (P01 HL108800 and R01AG071032), the David and June Trone Family Foundation, the Pollin Digital Innovation Fund, Sandra and Larry Small, CASCADE FH, Google, Amgen, and Merck. Dr. Martin has received material support from Apple and iHealth. Under a license agreement between Corrie Health and the Johns Hopkins University, the University owns equity in Corrie Health and the University and Dr. Martin are entitled to royalty distributions related to the Corrie technology. Additionally, Dr. Martin is a co-founder of and holds equity in Corrie Health. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. Furthermore, Dr. Martin reports personal consulting fees from Amgen, AstraZeneca, Chroma, Kaneka, NewAmsterdam, Novartis, Novo Nordisk, Sanofi, and 89bio. Michael Shapiro serves on the scientific advisory boards of Amgen, Ionis, Novartis and Precision BioScience and is a consultant for Ionis, Novartis, Regeneron, EmendoBio and Aidoc. Leandro Slipczuk has received institutional grants from Amgen and Philips and consulting honoraria from Amgen, BMS and Philips. Michael D. Shapiro is serving as Guest Editor and one of the Editorial Board members of this journal. We declare that Michael D. Shapiro had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Carmela Rita Balistreri. Others report no conflict., (Copyright: © 2023 The Author(s). Published by IMR Press.) more...
- Published
- 2023
- Full Text
- View/download PDF